Get the Stockscreener App
2.085
0.72%
0.015
Mural Oncology Plc stock is traded at $2.085, with a volume of 31,012.
It is up +0.72% in the last 24 hours and up +0.24% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.07
Open:
$2.08
24h Volume:
31,012
Relative Volume:
0.11
Market Cap:
$36.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.24%
1M Performance:
+0.24%
6M Performance:
+102.43%
1Y Performance:
-39.74%
1-Day Range:
$2.07
$2.09
1-Week Range:
$2.07
$2.09
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.08 | 35.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.80 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.56 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
806.96 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Trium Capital discloses 11% stake in Mural Oncology By Investing.com - Investing.com South Africa
Trium Capital discloses 11% stake in Mural Oncology - Investing.com
Is Mural Oncology plc stock attractive for growth ETFsShare Buyback & Growth Focused Stock Reports - newser.com
What candlestick patterns are forming on Mural Oncology plcMarket Activity Report & Safe Entry Momentum Tips - newser.com
Exit strategy if you’re trapped in Mural Oncology plc2025 Key Lessons & Low Risk High Win Rate Stock Picks - newser.com
Visualizing Mural Oncology plc stock with heatmapsMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Does Mural Oncology plc qualify in momentum factor screeningPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Citadel Group discloses 1.35% position in Mural Oncology By Investing.com - Investing.com Nigeria
Citadel Group discloses 1.35% position in Mural Oncology - Investing.com India
Combining machine learning predictions for Mural Oncology plcEarnings Recap Summary & Fast Entry High Yield Tips - newser.com
What recovery options are there for Mural Oncology plcJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
Citadel Group discloses 1.34% stake in Mural Oncology By Investing.com - Investing.com Nigeria
Citadel Group discloses 1.34% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.33% stake in Mural Oncology By Investing.com - Investing.com Nigeria
Citadel Group discloses 1.33% stake in Mural Oncology - Investing.com
Detecting support and resistance levels for Mural Oncology plc2025 Sector Review & Technical Analysis for Trade Confirmation - newser.com
What MACD signals say about Mural Oncology plcJuly 2025 Technicals & Safe Capital Growth Plans - newser.com
Visual trend scoring systems applied to Mural Oncology plc2025 Key Highlights & Capital Protection Trading Alerts - newser.com
Will Mural Oncology plc outperform the marketMarket Activity Recap & Precise Buy Zone Tips - newser.com
News impact scoring models applied to Mural Oncology plcQuarterly Profit Report & Fast Entry Momentum Trade Alerts - newser.com
Will Mural Oncology plc continue its uptrendWeekly Investment Summary & AI Optimized Trade Strategies - newser.com
Quantitative breakdown of Mural Oncology plc recent moveQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Is Mural Oncology plc stock undervalued vs historical averagesTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
Citadel Group discloses 1.32% stake in Mural Oncology By Investing.com - Investing.com Canada
Citadel Group discloses 1.32% stake in Mural Oncology - Investing.com India
Citadel Group discloses 1.56% stake in Mural Oncology By Investing.com - Investing.com Nigeria
Citadel Group discloses 1.56% stake in Mural Oncology - Investing.com India
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Mural Oncology Plc Stock (MURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Keson-Brookes Maiken | See Remarks |
Jul 18 '25 |
Sale |
2.48 |
2,158 |
5,352 |
71,406 |
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):